International study of MultiStem cell therapy for ischemic stroke
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms MASTERS-2
- Sponsors Athersys
- 13 Mar 2018 According to an Athersys media release, the company is planning to launch this trial in the second quarter 2018.
- 08 Aug 2017 According to an Athersys media release, design of this trial has received a Final Scientific Advice positive opinion from the European Medicines Agency. Also US FDA has granted Fast Track Designation for Multistem.
- 28 Sep 2016 According to an Athersys media release, this trial is expected to initiate in 2017.